EVP, Research & Investments
EVP, Research & Investments at Royalty Pharma plc, filing insider transactions between 2025-12-01 and 2026-06-24.
| SEC ↗ |
| 2026-01-30 | RPRX | Sale | 20.0K | $41.09 | $822K | SEC ↗ |
| 2026-01-23 | RPRX | Sale | 20.0K | $40.26 | $805K | SEC ↗ |
| 2026-01-16 | RPRX | Sale | 20.0K | $39.52 | $790K | SEC ↗ |
| 2026-01-09 | RPRX | Sale | 20.0K | $40.78 | $816K | SEC ↗ |
| 2026-01-02 | RPRX | Sale | 20.0K | $38.48 | $770K | SEC ↗ |
| 2025-12-26 | RPRX | Sale | 20.0K | $39.32 | $786K | SEC ↗ |
| 2025-12-19 | RPRX | Sale | 20.0K | $38.38 | $768K | SEC ↗ |
| 2025-12-16 | RPRX | Sale | 20.0K | $38.32 | $766K | SEC ↗ |
| 2025-12-05 | RPRX | Sale | 23.3K | $39.15 | $914K | SEC ↗ |
| 2025-12-05 | RPRX | Sale | 18.2K | $39.15 | $714K | SEC ↗ |
| 2025-12-01 | RPRX | Sale | 18.2K | $39.90 | $728K | SEC ↗ |
| 2025-12-01 | RPRX | Sale | 23.3K | $39.93 | $932K | SEC ↗ |